Close

What are ADC's

Our services

ADC Review
is made possible by:




NCT02314481 (DARWIN II) (Clinical Trial/ Ado-Trastuzumab Emtansine)

Study Title
Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity (DARWIN II) (NCT02314481)

Trial Description
DARWIN II is a multi-arm non-randomised phase II trial, Eligible patient will be those who relapse with stage IIIB/IV NSCLC, and are enrolled in the TRACERx study (clinical trials.gov ref. NCT02183883),

The trial will investigate assess if intra-tumour heterogeneity (clonal vs subclonal actionable mutation) is associated with PFS.

Patients without an actionable mutation will receive MPDL3280A a monoclonal antibody targeting anti-PDL1 in the first line setting.

Patients with BRAFV600 mutations, Her2 Amplification, ALK/RET gene rearrangements will be enrolled into arms treating with vemurafenib (Zelboraf®; Genentech, Inc/ Daiichi-Sankyo Co.), ado-trastuzumab emtansine (T-DM1, Kadcyla®; Genentech, Inc.) and alectinib respectively.

DARWIN II will include extensive exploratory biomarker analysis to investigate a number of genomic and immune markers that may predict response to MPDL3280A and help guide future clinical trial design.

This trial is sponsored by University College LondonF. Hoffmann-La Roche. [1]

Study Data

  • Condition: Non-small Cell Lung Cancer
  • Interventions:
  • Phase: II
  • Estimated Enrollment: 157
  • Start: June 2015
  • Estimated Completion: June 2022
  • Last verified: December 2014

Study Schematic

(Coming soon)

Click here to Return to Drug map


Last Editorial review: July 29, 2015
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.

Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.


Share

Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...


Skip to toolbar